Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease - Trial NCT06421597
Access comprehensive clinical trial information for NCT06421597 through Pure Global AI's free database. This Phase 2 trial is sponsored by Odense University Hospital and is currently Not yet recruiting. The study focuses on Osteoporosis Secondary. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Odense University Hospital
Timeline & Enrollment
Phase 2
May 01, 2024
Dec 01, 2025
Primary Outcome
Procollagen type 1 N-terminal propeptide (P1NP)
Summary
Previous studies have shown that there is a large inter-individual variability in the degree
 of bone loss during glucocorticoid treatment, and while some patients experience extensive
 bone loss other patients' bone mass remains stable. The aim of the study is to find a
 biomarker that can be used to identify individuals at risk of glucocorticoid-induced bone
 loss. The study will include 36 healthy volunteers, that will be randomized to receive either
 glucocorticoid treatment or placebo. During the study blood samples, bone marrow samples,
 bone tissue samples, and adipose tissue samples are taken and a mixed meal test is performed.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06421597
Non-Device Trial